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Carvedilol
 Third generation β –blocker (both β1 and β2)
 Possesses α1 – adrenergic blocking properties.
 β: α blocking ratio 7:1 to 3:1
 Antioxidant
 Calcium antagonist
Structure of carvedilol
1-(9H-carbazol-4-yloxy)-
3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol 
Carvedilol
 Improves myocardial function
 Attenuates or reverses adverse myocardial 
remodelling in HF
 Decreases  peripheral vascular resistance (α1 and 
β2 receptors).
 Lacks intrinsic sympathomimetic activity (ISA)
 Low levels of inverse agonist activity compared 
to other β - blockers
Carvedilol
 Originally used for hypertension
 Improves symptoms in patients with heart 
failure and stable angina pectoris.
 Decreases secondary cardiac events of the MI.
 Reduces infarct size following MI and 
reperfusion injury.
Pharmacological effects of Carvedilol
 Direct
 Indirect:
 Fall in IL-10
 Fall in TNF-α
 Fall in soluble TNF receptor levels
β – blocker use in diabetes I
 Improve outcomes more in patients with DM 
and history of AMI or CAD than in patients 
without DM.
 This is despite the fact that β – blockers elevate 
TG and lower HDL-C levels.
β – blocker use in diabetes II
 The positive effects of β – blockade relate to:
 Decrease in HR and BP
 Improved diastolic function
 Antiarrhythmogenic effects
 Anti-inflammatory effects
 Shifting of the metabolism of myocardium away 
from FFA towards glucose utilization.
 Turn around the total gene induction programme to 
reverse myocardial remodeling and improve 
ventricular function
Major problem with β – blockers use 
in diabetes
 Increased insulin resistance and worsening of 
glycaemic control, noted in:
 LIFE study (Lorsataan vs atenolol)
 COMET (Carvedilol vs Metoprolol)
 A community - based study
 The above have shown 22 – 28% increase in 
new onset diabetes.
GEMINI study
 Head to head trial of Carvedilol and 
Metroprolol.
 Subjects and outcome:
 Hypertensive diabetic patients receiving   RAS –
blocking agents
GEMINI trial
Figure 2. Glycosylated hemoglobin (HbAic ) at baseline and each maintenance month by treatment in the 
modified intention-to-treat population. The change from baseline to maintenance Month 5 (primary outcome) 
was significant (mean difference [SD], 0.13% [0.05%]; 95% confidence interval, −0.22% to −0.04%; 
p=0.004). Error bars indicate SD from mean. Reprinted with permission from JAMA. 2004;292:2227-2236.23
β – blockers in management of CKD
 High prevalence of CVD in people with CKD:
 Hypertension
 CAD
 MI
 Heart failure
CKD vs CVD
 Clear benefits of mortality obeserved for most β -
blockers in clinical trials (bisoprolol I & II, carvedilol, 
metoprolol SR etc).
 β – blockers relatively under-used in:
 CKD patients:
 Agodoa et al 30%
 USRDS 20%
 Patients on dialysis:
 Agodoa et al 24% dialysis patients with CAD
 Similar trend in predialysis patients.
 Reason for under - utilization: fear of adverse  
haemodynamic effects on renal physiology and effects 
on lipids and glucose levels.
Rationale for use of β – blockers in 
CKD
 There is sympathetic over activity in patients 
with CKD.
 Sympathetic overdrive has a role in:
 Genesis of HTN
 Complications of CVD
 Progression of kidney disease
β – blockers vary significantly in their 
pharmacologic properties which determine how 
well they work and how tolerable they will be in 
patients with CKD
Pharmacological properties of β -
blockers
 Lipid solubility
 Cardioselectivity
 Metabolism and excretion.
 Adjunctive properties:
 Vasodilatory
 Antioxidant
 Calcium – blocking activity
 Metabolic factors:
 Lipoproteins
 Glycaemic control
 Hyperkalaemia
Lipid solubility I
Lipophilic agents undergo extensive first pass 
hepatic metabolism with relatively very little 
being excreted unchanged in urine
Lipid solubility II
Hydrophilic agents are excreted primarily by the 
kidney and require dose adjustments in patients 
with ESRD.
Lipid solubility III
Hydrophilic agents agents may yield low blood 
levels due to poor absorption after oral 
administration
Cardioselectivity I
 β1 – selective blockers are cardiospecific and 
result in reduced CO, HR and BP
Cardioselectivity II
 β1 – β2 blockers antagonize the effects of  
catecholamine stimulation on                    β –
adrenergic receptors in resistance vessels as well 
as the myocardium.
 β2 – blockade downgrades the pro-arrhythmic 
effect of NE.
Cardioselectivity III
 Inhibititon of β2 vasodilation leaves the reflex 
α1- mediated  vasoconstrictor response to 
arterial underfilling unopposed in the face of 
decreased BP or CO.
 The effects of β – blockade amplified by 
reduction in production of renin by the JGA.
Addition of α1-inhibiting activity to β-
adrenergic antagonist
 Blocks reflex vasoconstriction
 May increase blood flow to skeletal muscle there 
improving glucose availability and disposal.
 Both non-selective and selective β-blockers can 
increase insulin resistance.
 α-blocking activity if increased may improve 
insulin sensitivity in both diabetic and non-
diabetics.
Conclusion
Addition of α1-blocking activity to certain 
β–blockers may impact both diabetes and 
ateriosclerotic CVD by promoting  better 
glycaemic control with less compensatory 
hyperinsulinaemia and fewer proatherogenic 
changes in serum lipids
Effect of β-blockers on lipid metabolism
 β1 selective and non-selective β-blockers:
 Increase blood levels of TG
 Lower levels of HDL-C
 α1-blocking activity:
 Lowers TG
 Raises HDL-C
Summary of the effects of some common 
β-blockers
↑, increases with use of drug; ↓, decreases with use of drug; ↔,remains the same with use of drug; CKD, chronic 
kidney disease; ESRD,end-stage renal disease; GFR, glomerular filtration rate; HDL,high-density lipoprotein; N, 
no; RBF, renal blood flow; RVR, renalvascular resistance; Y, yes. 
  Propranolol Metoprolol Atenolol Labetalol Carvedilol 
Lipophilic Y Y N Y Y 
Nonselective (β1/β2) Y N N Y Y 
Cardioselective (β1) N Y Y N N 
α1-blockade N N N Y Y 
Insulin sensitivity ↓ ↓ ↓ ↔ ↑ 
Serum triglycerides ↑ ↑ ↑ ↔ ↓ 
Serum HDL cholesterol ↓ ↓ ↓ ↔ ↑ 
Hyperkalemia in ESRD Y N N Y N 
Renal effects in CKD 
 RVR ↑ ↓ ↔ ↔ ↓ 
 RBF ↓ ↔ ↔ ↔ ↑ 
 GFR ↓ ↔ ↔ ↔ ↑ 
 
Properties of carvedilol
 Lowers blood pressure in both younger and older black 
and white patients
 Reduces peripheral resistance
 Does not reduce cardiac output or renal function in 
long-term studies
 Has a neutral effect on lipids and glucose
 Is well tolerated by most patients
 Possesses antioxidant effects in pharmacologic studies 
(inhibits oxygen-free radicals. This action may be 
important in slowing down the process of atherogenesis 
and protecting against brain tissue injury)
Properties of carvedilol
 Reduces morbidity and mortality in patients with 
congestive heart failure who are already being treated 
with angiotensin converting enzyme inhibitors, 
diuretics, and digitalis (reduces preload and afterload).
 Reduces infarct size to a significant degree in animal 
models and improves survival (effect not demonstrated 
with other b-blockers).
 Has antiproliferative effects on smooth muscle cells (in 
response to angiotensin II, platelet-derived growth 
factor, etc)
Nebivolol
 Relatively new lipophilic β1-blocker approved 
for HTN.
 Devoid of Intrinsic Sympathomimetic 
Membarane Stabilizing  Activity.
 Has NO – mediated vasodilatory effect.
 Glucose and lipid not affected.
 Not much tested clinically in other areas.
FIGURE 2. Changes in serum lipids in a 6-month double-blind study of 220 hypertensive patients receiving 
either carvedilol (25 to 0 mg/day) or captopril (25 to 50 mg/day). *P , .0001 versus baseline. Start 5 end of 4-
week placebo washout phase; HDL, high-density lipoprotein; LDL, low density lipoprotein; TC, total 
cholesterol; TG, triglyceride. Data from Hauf-Zachariou et al.8
FIGURE 3. Percentage of patients with reduction or increase in urinary albumin level with carvedilol compared to 
other antihypertensive agents (reproduced from Marchi and Ciriello,24 with permission.).
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